Study of gamma interferon agonists/mimetics

γ干扰素激动剂/模拟物的研究

基本信息

  • 批准号:
    7638699
  • 负责人:
  • 金额:
    $ 10.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

Gamma interferon (IFN_() is an essential cytokine for mediation of functions that are obligatory for good health, particularly that mediated through or maintained through CD4 T- helper 1 (Thl) cells. Further, IFN_, possesses direct antiviral and anticellular (antitumor) activity. Thus, the development of IFN1, mimetics has important implications for immune- therapy in infectious diseases and cancer. The Specific Aims listed below directly test both the rational development of such mimetics as well as their use in the mediation of IFN_, activity. 1. Synthesis of IFN1, peptide mimetics based on sequence and structural similarity to biologically active IFNI, C-terminal peptides. 2. Compare several methods for delivery of IFN_, peptides intracellularly, including chemical modification and use of molecular expression systems. 3. Determine signaling function of IFN_, peptide mimetics in terms of JAK/STAT activation, upregulation of tumor suppressor gene p21 wAF/cIP, and down regulation of neu/HER-2 protooncogene in cancer cells. 4. Determine cellular function of IFN_, peptide mimetics in terms of antiviral activity, anticellular (antitumor) activity, and upregulation of MHC class II molecules. 5. Determine biological activity of IFN_, mimetic peptides in mouse models of virus infection and cancer.
γ干扰素(IFN_())是一种重要的细胞因子,可介导以下功能

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HOWARD M JOHNSON其他文献

HOWARD M JOHNSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HOWARD M JOHNSON', 18)}}的其他基金

Treatment of EAE by Small Peptide Mimetics of SOCS-1
SOCS-1 的小肽模拟物治疗 EAE
  • 批准号:
    7469505
  • 财政年份:
    2006
  • 资助金额:
    $ 10.08万
  • 项目类别:
Treatment of EAE by Small Peptide Mimetics of SOCS-1
SOCS-1 小肽模拟物治疗 EAE
  • 批准号:
    7141899
  • 财政年份:
    2006
  • 资助金额:
    $ 10.08万
  • 项目类别:
Treatment of EAE by Small Peptide Mimetics of SOCS-1
SOCS-1 的小肽模拟物治疗 EAE
  • 批准号:
    7665343
  • 财政年份:
    2006
  • 资助金额:
    $ 10.08万
  • 项目类别:
Treatment of EAE by Small Peptide Mimetics of SOCS-1
SOCS-1 的小肽模拟物治疗 EAE
  • 批准号:
    7233659
  • 财政年份:
    2006
  • 资助金额:
    $ 10.08万
  • 项目类别:
Study of gamma interferon agonists/mimetics
γ干扰素激动剂/模拟物的研究
  • 批准号:
    6798822
  • 财政年份:
    2003
  • 资助金额:
    $ 10.08万
  • 项目类别:
Study of gamma interferon agonists/mimetics
γ干扰素激动剂/模拟物的研究
  • 批准号:
    7777372
  • 财政年份:
    2003
  • 资助金额:
    $ 10.08万
  • 项目类别:
Study of gamma interferon agonists/mimetics
γ干扰素激动剂/模拟物的研究
  • 批准号:
    7021366
  • 财政年份:
    2003
  • 资助金额:
    $ 10.08万
  • 项目类别:
Study of gamma interferon agonists/mimetics
γ干扰素激动剂/模拟物的研究
  • 批准号:
    7464818
  • 财政年份:
    2003
  • 资助金额:
    $ 10.08万
  • 项目类别:
Study of gamma interferon agonists/mimetics
γ干扰素激动剂/模拟物的研究
  • 批准号:
    7445465
  • 财政年份:
    2003
  • 资助金额:
    $ 10.08万
  • 项目类别:
Study of gamma interferon agonists/mimetics
γ干扰素激动剂/模拟物的研究
  • 批准号:
    7568248
  • 财政年份:
    2003
  • 资助金额:
    $ 10.08万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 10.08万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 10.08万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 10.08万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 10.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 10.08万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 10.08万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 10.08万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 10.08万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 10.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 10.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了